| Dr Douglas C Mccorkle, MD | |
|
10 Crossroads Drive, Suite 100, Owings Mills, MD 21117 | |
| (410) 363-7172 | |
| (410) 363-7188 |
| Full Name | Dr Douglas C Mccorkle |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 43 Years |
| Location | 10 Crossroads Drive, Owings Mills, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124111844 | NPI | - | NPPES |
| 3383624 | Other | MD | US HEALTHCARE |
| 31779 | Other | MD | ALLIANCE |
| 31779 | Other | MD | MAMSI |
| 44425 | Other | MD | INJURED WORKERS INS FUND |
| 42461004 | Other | MD | BLUECROSS BLUESHEILD |
| KFN6DO | Other | MD | BLUECROSSBLUESHIELD |
| 1000254 | Other | MD | UNITED HEALTHCARE |
| 31779 | Other | MD | MDI PA |
| 4137034 | Other | MD | AETNA |
| J1140001 | Other | MD | BCBS FEDERAL |
| J1140001 | Other | MD | BLUECHOICE |
| 31779 | Other | MD | OPTIMUM CHOICE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | D0033742 (Maryland) | Primary |
| Entity Name | Douglas C. Mccorkle Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013192848 PECOS PAC ID: 4486552007 Enrollment ID: O20040107000113 |
News Archive
The summer is officially here and more people are playing sports and exercising outdoors. Experts from NYU Langone's Center for Musculoskeletal Care (CMC) offer tips to avoid injuries during these warmer months.
More support is needed for fosters carers looking after LGBTQ young people, according to new research led by the University of East Anglia (UEA).
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas C Mccorkle, MD 10 Crossroads Drive, Suite 100, Owings Mills, MD 21117 Ph: (410) 363-7172 | Dr Douglas C Mccorkle, MD 10 Crossroads Drive, Suite 100, Owings Mills, MD 21117 Ph: (410) 363-7172 |
News Archive
The summer is officially here and more people are playing sports and exercising outdoors. Experts from NYU Langone's Center for Musculoskeletal Care (CMC) offer tips to avoid injuries during these warmer months.
More support is needed for fosters carers looking after LGBTQ young people, according to new research led by the University of East Anglia (UEA).
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Chief Executive Officer, Peter Parker, will provide details on Cequent's planned launch of its clinical program and highlight strategy and development goals in a company update scheduled for 3 p.m. on Tuesday, October 27, 2009, at the 2009 BIOCOM Investor Conference.
Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents ages 13 to 17. The approval is based on study data demonstrating that Vyvanse improved ADHD symptoms compared to placebo in adolescents with ADHD. Vyvanse is also indicated for the treatment of ADHD in children ages 6 to 12 years, and adults.
› Verified 6 days ago
Yemeng Lu-myers, M.D., M.P.H Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 23 Crossroads Dr Ste 400, Owings Mills, MD 21117 Phone: 410-356-2626 Fax: 410-356-8945 | |
Mark A Mashburn, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 23 Crossroads Dr, Suite 400, Owings Mills, MD 21117 Phone: 410-356-2626 Fax: 410-356-8945 | |
Kevin Connolly, Otolaryngology Medicare: Medicare Enrolled Practice Location: 23 Crossroads Dr Ste 400, Owings Mills, MD 21117 Phone: 410-356-2626 | |
Michael David Weiss, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 23 Crossroads Dr, Suite 400, Owings Mills, MD 21117 Phone: 410-356-2626 | |
Tam N Nguyen, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 23 Crossroads Dr, Suite 400, Owings Mills, MD 21117 Phone: 410-356-2626 Fax: 410-356-8945 | |
Daniel Victor Santos, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 23 Crossroads Dr, Suite 400, Owings Mills, MD 21117 Phone: 410-356-2626 |